SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

Company

Candel Therapeutics, Inc.

Filed

February 14, 2022

Accession Number

0001387131-22-001918

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →